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Abstract
Objectives
Lifestyle combined interventions are a key strategy for preventing type-2 diabetes (T2DM)
in overweight or obese subjects. In this framework, LIPOXmax individualized training,
based on maximal fat oxidation [MFO], may be a promising intervention to promote fat mass
(FM) reduction and prevent T2DM. Our primary objective was to compare three training pro-
grams of physical activity combined with a fruit- and vegetable-rich diet in reducing FM in
overweight or obese women.
Design and setting
A five months non-blinded randomized controlled trial (RCT) with three parallel groups in La
Réunion Island, a region where metabolic diseases are highly prevalent.
Subjects
One hundred and thirty-six non-diabetic obese (body mass index [BMI]: 27–40 kg/m2)
young women (aged 20–40) were randomized (G1: MFO intensity; G2: 60% of VO2-peak
intensity; G3: free moderate-intensity at-home exercise following good physical practices).
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Outcomes
Anthropometry (BMI, bodyweight, FM, fat-free mass), glucose (fasting plasma glucose,
insulin, HOMA-IR) and lipid (cholesterol and triglycerides) profiles, and MFO values were
measured at month-0, month-3 and month-5.
Results
At month-5, among 109 women assessed on body composition, the three groups exhibited
a significant FM reduction over time (G1: -4.1±0.54 kg; G2: -4.7±0.53 kg; G3: -3.5±0.78 kg,
p<0.001, respectively) without inter-group differences (p = 0.135). All groups exhibited sig-
nificant reductions in insulin levels or HOMA-IR index, and higher MFO values over time
(p<0.001, respectively) but glucose control improvement was higher in G1 than in G3 while
MFO values were higher in G1 than in G2 and G3. Changes in other outcome measures
and inter-group differences were not significant.
Conclusion
In our RCT the LIPOXmax intervention did not show a superiority in reducing FM in over-
weight or obese women but is associated with higher MFO and better glucose control
improvements. Other studies are required before proposing LIPOXmax training for the pre-
vention of T2DM in overweight or obese women.
Trial Registration
ClincialTrials.gov NCT01464073
Introduction
Over the past three decades, the burden of obesity has nearly doubled worldwide [1]. Indeed,
according to a recent World Health Organization (WHO) report, 1.46 billion adults were over-
weight (body mass index [BMI] 25 kg/m²) in 2008, and of these, 205 million men and 297
million women were obese (BMI 30 kg/m²). In La Réunion Island, Favier and co-workers
confirmed in the REDIA study that women have a higher prevalence of overweight or obesity
than men (47% vs 43%, BMI> 25 kg/m² p = 0.002) [2].
The causal relationship between obesity, metabolic syndrome (MS) and conditions such as
type-2 diabetes mellitus (T2DM), cardiovascular diseases (CVD) and cancer is now well docu-
mented. [3] Thus, in our setting, sedentary lifestyle and the high prevalence of obesity may par-
tially explain the high prevalence of T2DM in the 30–69 age group for women (17.3%) [2,4]. In
line with this picture, the literature dedicated to preventive strategies for obesity and related
complications provides evidence that lifestyle interventions combining regular physical activity
(PA) and diet were cost-effective [5–8]. As visceral adiposity is the milestone of cardiovascular
complications, it is thus imperative to propose preventive measures based on fat mass (FM)
reduction in obese people. However, despite the high level of proofs and indisputable useful-
ness, the level of prescription of strategies based on regular PA remains poor in this population.
According to the American College of Sports Medicine, a dose–response is expected between
the amount of PA and the intensity of weight reduction: “less than 150 minutes a week of PA
promotes minimal weight loss, PA> 150 min/wk results in moderate weight loss of ~2–3 kg,
LIPOXmax Réunion
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PA between 225–420 min/week results in 5–7.5 kg weight loss”. Importantly, “PA improves
weight loss when diet restriction is modest but not when diet restriction is substantial” [9]. In
this framework, a growing body of evidence has shown that the benefits of PA in obese people
are limited when it is not individualized, regular, and based on a “moderate intensity”. The
concept of individualization of exercise training has led some experts to recommend the use of
sub-maximal self-parameters for guiding the prescription of PA exercises [10,11]. Moreover,
Salvadego and coll [12]. have proposed that PA prescription in obese people takes into account
the "metabolic answer" to the effort, represented by the adaptation kinetics of several parame-
ters including oxidative metabolism and exercise tolerance biomarkers, and not only the maxi-
mal oxygen consumption (VO2 peak) or the maximal heart rate (HR peak).
In this context, the threshold of maximal lipid oxidation has been sought [13]. This is usu-
ally measured by indirect calorimetry during an incremental exercise test. According to the bal-
ance of carbohydrate and lipid utilization during exercise [14], carbohydrates oxidation (CHO)
increases proportionally to the intensity of exercise, whereas lipids oxidation reaches a maxi-
mum at an intensity defining the “LIPOXmax” and then decreases. LIPOXmax differs between
individuals, and its measure allows the determination, for each subject, of the optimal intensity
in an effort to achieve maximal lipid consumption during exercise sessions. So far, the use of
indirect calorimetry enables the prescription of an individualized training program in order to
optimize the oxidation of lipids. Several works have highlighted the efficiency of LIPOXmax
training on FM loss, glucose control and muscular metabolism in obese or diabetic subjects
[15–27]. However, in these studies the lack of control group did not allow to conclude whether
the improvements are due to the LIPOXmax training or to the endurance exercise training per
se. To the best of our knowledge, no study has yet compared the individualized LIPOXmax
training to a standardized training guided by the percentage of VO2 peak, or by the Guideline
of Good Physical Practices (GPP) in obese women.
Alongside individualized PA training programs, the WHO encourages the consumption of
at least five portions of fruits and vegetables per day [28]. Micronutrients, fibre, and phyto-
chemicals are associated with risk reductions of CVD [29] and T2DM [30]. Furthermore, FM
loss is facilitated when a fruits and vegetables diet is combined with regular PA [9]. Unfortu-
nately, obese subjects consume fewer vitamins and antioxidants of fruits and vegetables origin
compared with non-obese subjects [31–33]. Thus, fruits and vegetables consumption must be
strongly encouraged in this at-risk population.
The primary objective of the “LIPOXmax-Réunion” study was to compare three PA training
programs combined with fruits and vegetables supplementation, in reducing FM in overweight
or obese sedentary women. Secondary objectives were to assess changes in body composition,
glucose and lipid profiles, and maximal fat oxidation measures.
Methods
The protocol of the LIPOXmax-Réunion RCT and supporting CONSORT checklist are avail-
able as supporting information; see S1 Protocol (full protocol in French), S2 Protocol (brief
English translation), and S1 CONSORT Checklist.
Design and setting
The “LIPOXmax-Réunion” study was a non-blinded, randomized controlled trial (RCT) with
three parallel groups. All participants were recruited in a single centre (CHU Sud-Réunion)
between November 2011 and April 2012 and followed-up over five months, between December
2011 and September 2012.
LIPOXmax Réunion
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Participants
After providing written consent for participation, eligible overweight or obese women were
enrolled in the study. The eligible criteria were, as follows: aged between 20 and 40, overweight
or obese (BMI: 27 to 40 kg/m²), sedentary life style (< 2 hours of PA per week), clinically stable,
namely non-diabetic (fasting plasma glucose< 7 mmol/L, HbA1c< 6.5%), and able to practise
exercise training.
Non-inclusion criteria were hypertension (140/90 mmHg), contra-indication to PA train-
ing, cardiovascular and/or respiratory disease diagnosed by a cardiorespiratory exercise test,
myopathy, cancer, acute and chronic inflammatory diseases, end-stage renal disease, digestive
system surgery, previous treatment by steroids, thyroid hormone HRT, antidepressants or neu-
roleptics, pregnancy, participation in the previous month in a program of training or a diet.
Ethics and funding
This research was approved by the Ethical Research Committee of the University of Bordeaux
III and was registered with an approved ICMJE clinical trial registry: NCT01464073
ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01464073. This research was sup-
ported by grants of La Réunion island authorities (CPER 2012) and by the European Research
and Development Fund (POCT FEDER 2007–2013).The sponsors played no role in determin-
ing the study design, data collection, analysis and interpretation, or writing of the report. The
corresponding author had full access to all the data and had the final responsibility for the deci-
sion to submit for publication.
Randomization
After inclusion, subjects were randomly assigned to one of the three groups: G1 (LIPOXmax);
G2 (60% VO2max); G3 (GPP at-home, 30 minutes minimum per day at a moderate intensity).
Randomization was stratified on baseline BMI status defined as follows: stratum 1:
27.0 BMI< 30.0 kg/m², stratum 2: BMI 30.0 kg/m². The two lists of randomization were
provided by the statistician of the Centre for Clinical Investigation (AF) before starting the
research, using Ralloc program of Stata v10.01 (randomization by block with equal block
size = 3, and balanced allocation ratio 1:1:1). The statistician gave the individual intervention’s
assignment to the research coordinator who informed the participant.
Intervention
Exercise training programs. All training sessions for G1 and G2 were performed in the
hospital on cyclo-ergometers (CARE–Sprinter XP) and were supervised by a PA coach (JM).
G1 (LIPOXmax) was conducted at a low-endurance intensity eliciting the maximal lipid oxida-
tion measured by indirect calorimetry, four times a week for 55 minutes. G2 (60% VO2max)
subjects exercised four times a week for 35 minutes at moderate-intensity, corresponding to
60% of the VO2 peak. The duration of PA was levelled between groups to an isocaloric exercise
per session of 20 kJ.kg Fat Free Mass-1. G3 (GPP at-home) subjects were assigned a daily free
practice of 30 minutes of moderate-intensity exercise. All the participants were given a pedom-
eter (Dista Newfeel 4001), a HR monitor (Kalenji 3001) and a PA booklet where the duration
(minutes), intensity (recorded on a Borg scale graded 1 to 10), and the type of exercise had to
be noted. This booklet was checked twice a month.
Dietary intervention. To ensure a healthy balanced diet throughout the RCT, all subjects
participated in a nutritional educational workshop conducted by a dietician prior to the start of
LIPOXmax Réunion
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the PA programs. Over the 5-month intervention period, all subjects received a free supple-
mentation of five portions of fruits and vegetables a day.
Outcome measures. The primary outcome was the FM change expressed in kilograms
and measured by Dual X-ray absorptiometry (DXA–GE Healthcare, Little Chalfont, United
Kingdom) between the inclusion (M0) and the end of the intervention at the fifth month (M5).
Secondary outcomes were measured at inclusion (M0), at the third- (M3) and at the fifth-
month (M5). They included total body mass, FM, fat free mass (FFM), plasma lipids (total
cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides), fasting plasma glucose (FPG),
glycosylated haemoglobin (HbA1c), insulin resistance (as measured by the HOMA-IR index),
and the exercise’s metabolic profile with the determination of the maximal fat oxidation
(MFO).
Anthropometric measures. After a whole fasting night, total body mass and regional
body composition were measured by DXA. Height was measured to the nearest 0.5 cm using a
standardized height gauge. BMI was calculated as weight (kg)/height² (m).
Maximal cardiorespiratory exercise test. Cardiorespiratory fitness was measured during
a cyclo-ergometer incremental test (Ergoline Bosch 500, Berlin, Germany). Oxygen (VO2) and
carbon dioxide (CO2) were registered by a breath by breath analysis and heart rate (HR) was
recorded continuously by a 12-lead electrocardiogram (Ergostik, Geratherm Medical AG,
Geschwenda, Germany). After a warm upload of 20 Watts for two minutes, 15 Watts incre-
ments were applied each minute, up to exhaustion. Maximal oxygen consumption (VO2peak)
was calculated in the last 30 seconds of the test. Maximal aerobic power output (MAP in W)
was determined as the power developed at the latest accomplished workload.
Metabolic exercise test. After a whole fasting night, the women performed an exercise test
on a cyclo-ergometer connected to the analyser for gas exchange measurements (VO2 and
VCO2) and to the HR monitor. The test consisted of a progressive five- to six-minute steady
state workload corresponding to 20%, 30%, 40%, 50%, 60% of MAP as generally used to indi-
vidualize the increment of testing [13,17]. VO2, VCO2 and HR were recorded during the last
two minutes of each stage in order to calculate the substrate oxidation flow rates [34].
Maximal Fat Oxidation. Substrate oxidation was calculated from the measurement of the
respiratory exchange ratio (RER = VCO2/VO2) to determine whole body substrate oxidation.
RER is the most widely used method for determination of fuel utilization. Fat oxidation rates
were calculated from the gas exchange measurements according to the non-protein respiratory
quotient technique using the following equation: Fat (mg.min-1) = -1.7012×VCO2 + 1.6946×
VO2 (gas volume expressed in ml.min
-1) [35].
The MFO is the point where fat oxidation induced by increasing workload reaches a maxi-
mum, followed by a decrease when CHO becomes the predominant fuel. The corresponding
HR expressed as beats per minute (bpm) at MFO intensity was recorded individually and then
applied to control the intensity of exercise training in G1 (LIPOXmax).
Statistical analysis
Prior sample size calculation. The primary outcome measure was the individual FM
change from the inclusion to the end of the follow-up, five months later (ΔM5-M0, in kg). To the
best of our knowledge, LIPOXmax intervention, sustained over five months, had never been
compared to other PA training programs in a population of young overweight or obese
women; thus it was not possible to use an expected effect value in sample size calculation. As a
consequence, our RCT was designed to detect a minimal FM difference of 1.5 kg (standard
deviation: ± 2.0 kg) between G1 and G2. For multiple comparison purposes, α risk was set to
LIPOXmax Réunion
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1.67% using Bonferroni correction (0.05:3), statistical power (1-β) to 80%, in bilateral
hypothesis.
Under these conditions, 38 women per group had to be recruited and followed to satisfy the
analysis.
This number was raised to 42 to anticipate a 10% loss due to protocol deviation or loss-to-
follow-up, leading to the enrolment of a total of 126 women.
Statistical methods. Data were summarized by mean ± standard deviation (SD) or 95%
confidence interval (95% CI), median (interquartile range) and percentages. Baseline inclusion
characteristics were compared between groups using one-way ANOVA or Kruskal-Wallis non
parametric test for quantitative variables, or using Chi2 test or Fisher exact test for qualitative
variables, as appropriate. Baseline exercise tests at inclusion were compared between groups
using one-way ANOVA or Kruskal-Wallis non parametric test, as appropriate. Changes in
anthropometric characteristics were compared between groups using one-way ANOVA or
Kruskal-Wallis non-parametric test, as appropriate, post-hoc analysis being performed with
Student-T tests. Repeated ANOVA measures allowed estimating time effect (M0-M3-M5),
group effect (G1-G2-G3) and the interaction timegroup. Wilcoxon rank-sum test was used to
analyse the differences between G1 and G2.
The primary outcome and the other five-month changes were analyzed between M5 and
M0 within the group of subjects for whom these data were available. The longitudinal evolution
of metabolic parameters was analyzed for the subjects for whom the M0, M3 and M5 data were
complete. Missing observations were excluded. Except for the aforementioned post hoc analy-
sis, the significance level was set to 5%. Analyses were carried out using SAS1 version 9.2 (SAS
Institute Inc., Cary, NC, USA).
Results
Selection of participants
The LIPOXmax–Réunion flow chart depicting the distribution of the participants throughout
the RCT is presented in Fig 1. Of the 156 women eligible for the study, 136 were enrolled and
randomized between November 2011 and April 2012. Of these, 109 subjects were subsequently
followed-up five months between December 2011 and September 2012. They were assessed at
M0 and M5 (80.1% of all randomised subjects), and among them, 103 had satisfied the com-
plete protocol with M0, M3 and M5 evaluations (75.7% of all randomised subjects). No selec-
tion bias was observed between randomized participants and non-participants, regardless of
the definition of participation used (subjects assessed at M0-M5, or at M0-M3-M5).
Baseline characteristics
The physical characteristics of subjects are presented in Table 1. Women were aged on average
30 years old. More than three-quarters of them were obese (BMI 30 kg/m²) and 86.6% had a
high waist circumference according to the NCEP/ATP-III thresholds.
Overall, the percentage of FM was 47.1% and the one of FFM 51.3%. Eighty percent were
insulin resistant (HOMA-IR index> 2.5). Mean of MFO was of 153.4 mg/min. At M0, there
was no difference among the three groups in socio-demographic and anthropometric data
(Tables 1 and 2). There were no differences between subjects who dropped out and subjects
who participated in all of the longitudinal study, which could distort the basic characteristics
(Fig 1). Analyses of bias of selection are available as supporting information; see S1–S4 Tables.
LIPOXmax Réunion
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Implementation of training programs
For G1 and G2, PA was levelled on the maximal and metabolic cardiorespiratory values. To
obtain the same energy expenditure between each group (20 kJ.kg FFM-1), G1 training sessions
were longer in duration than those for G2 (53 min vs. 37 min, p<0.001). The intensity of exer-
cise was lower for G1 than for G2 (45% vs. 60% VO2max; 119 vs. 140 bpm; 42 vs. 76 Watts;
p<0.001, respectively).
G3 women practised on average two different types of exercise. The examination of the PA
booklets revealed that 80.6% of the women practised walking, 45.2% fitness or gymnastics,
48.4% outdoor biking, 29.0% dancing (Zumba), 19.4% swimming and 12.9% indoor biking.
The weekly average number of PA sessions was 3.4 (±0.9 SD, min-max: 0.8–4.7). The weekly
average time spent on physical exercises was 197.7 minutes (± 67.5 min. SD, min-max: 48.6–
350.2 min.). Self-perceived intensity reported using the Borg scale ranged from three to five.
Changes in anthropometric and body composition parameters
Anthropometric and body composition parameters were measured by DXA at M0 and M5.
Accordingly, the evolution of DXA measures were analysed for the 109 subjects who had fully
completed M5 data. Results are summarized in Table 3.
Fig 1. LIPOXmax Réunion Flow chart.
doi:10.1371/journal.pone.0139246.g001
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Table 1. Baseline inclusion characteristics for LIPOXmax-Réunion randomized controlled trial participants.
All groups G1: LIPOXmax G2: 60% VO2max G3: GPP at home p-value
N = 136 N = 46 n = 45 n = 45
Socio-demographic
characteristics
Age (years) 30.1 ± 5.6 30.5 ± 5.9 29.0 ± 4.9 30.9 ± 5.8 0.186*
School level:
Secondary school (pupils from 10
to 15)
8.8% 15.2% 8.9% 2.2% 0.134*
Upper forms (pupils from 15 to 18) 46.3% 47.8% 37.8% 53.3%
A-level or Higher school 44.9% 37.0% 53.3% 44.4%
Number of children at home † 1.0 (1.0–2.0) 2.0 (1.0–2.0) 1.0 (1.0–2.0) 2.0 (1.0–2.0) 0.167*
Number of children ‡ 2.0 (1.0–2.0) 2.0 (1.0–3.0) 1.0 (1.0–2.0) 2.0 (1.0–3.0) 0.181*
Recipient of CMU 64.0% 69.6% 62.2% 60.0% 0.609
Living in a couple 51.5% 54.3% 42.2% 57.8% 0.300
Anthropometric characteristics
Height (cm) 161.5 ± 5.8 162.6 ± 4.6 160.6 ± 6.6 161.4 ± 6.1 0.263
Weight (kg) 86.6 ± 11.6 88.2 ± 11.5 85.5 ± 12.1 86.1 ± 11.5 0.518
BMI (kg/m²) 33.1 ± 3.5 33.3 ± 3.8 33.1 ± 3.5 33.0 ± 3.3 0.950*
< 30 kg/m² 24.3% 21.7% 24.4% 26.7% 0.860
 30 kg/m² 75.7% 78.3% 75.6% 73.3%
Waist size (cm) 97.9 ± 9.0 98.7 ± 9.4 96.3 ± 8.5 98.8 ± 8.9 0.342
< 88 cm 12.5% 6.5% 17.8% 13.3% 0.256*
 88 cm 87.5% 93.5% 82.2% 86.7%
Hips (cm) 121.0 ± 8.3 121.0 ± 8.5 121.1 ± 9.3 121.0 ± 7.2 0.996
Report Waist / Hips 0.8 ± 0.1 0.8 ± 0.1 0.8 ± 0.1 0.8 ± 0.1 0.302
Report Waist / Hips: < 0.9 89.0% 87.0% 88.9% 91.1% 0.941*
 0.9 11.0% 13.0% 11.1% 8.9%
Fat mass (kg) 39.9 ± 7.9 40.2 ± 7.8 40.2 ± 8.5 39.3 ± 7.4 0.819
Fat mass (%) 47.1 ± 3.8 46.6 ± 3.8 47.9 ± 4.0 46.7 ± 3.6 0.195
Anthropometric characteristics
Troncal Fat Mass (kg) 18.6 ± 4.6 18.8 ± 5.0 18.6 ± 4.4 18.3 ± 4.6 0.885
Android Fat Mass (kg) 3.4 ± 1.0 3.4 ± 0.9 3.4 ± 1.0 3.4 ± 1.0 0.933
Gynoid Fat Mass (kg) 7.0 ± 1.5 7.0 ± 1.4 7.2 ± 1.8 6.9 ± 1.3 0.542
Fat Free Mass (kg) 44.2 ± 4.8 45.4 ± 5.0 42.9 ± 4.3 44.3 ± 5.0 0.059*
Fat Free Mass (%) 51.3 ± 3.6 51.8 ± 3.6 50.6 ± 3.8 51.7 ± 3.4 0.206
Troncal Fat Free Mass (kg) 18.5 ± 2.3 19.0 ± 2.4 17.9 ± 1.9 18.6 ± 2.5 0.051
Android Fat Free Mass (kg) 2.9 ± 0.4 3.0 ± 0.4 2.8 ± 0.3 3.0 ± 0.4 0.050
Gynoid Fat Free Mass (kg) 6.9 ± 0.9 7.1 ± 0.8 6.8 ± 0.9 6.9 ± 0.9 0.234
Blood pressure
Systolic blood pressure (mm Hg) 117.0 ± 9.9 117.8 ± 9.2 115.7 ± 11.4 117.5 ± 9.1 0.565
Diastolic blood pressure (mm Hg) 74.4 ± 8.5 74.8 ± 8.8 74.3 ± 8.7 74.3 ± 8.1 0.950
Lipid proﬁle
Total Cholesterol (mmol/L) 4.5 ± 0.8 4.5 ± 0.8 4.5 ± 0.9 4.6 ± 0.8 0.890
LDL Cholesterol (mmol/L) 2.8 ± 0.7 2.8 ± 0.8 2.8 ± 0.7 2.8 ± 0.7 0.929
HDL Cholesterol (mmol/L) 1.2 ± 0.3 1.3 ± 0.3 1.2 ± 0.3 1.3 ± 0.3 0.773
HDL-C/LDL-C ratio 0.48 ± 0.21 0.49 ± 0.25 0.47 ± 0.17 0.49 ± 0.19 0.699*
Triglycerides (mmol/L) 1.1 ± 0.5 0.9 ± 0.3 1.1 ± 0.6 1.2 ± 0.6 0.297*
Glucose proﬁle
(Continued)
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At M5, each group (G1, G2, G3) exhibited a significant decrease in total body weight over
time (intra-group differences: -5.0±0.6; -5.4±0.7; -3.5±0.9 kg respectively, p<0.001), BMI
(-1.8±0.2; -2.1±0.3; -1.4±0.3 kg/m², p<0.001) and FM (-4.1±0.5; -4.7±0.5; -3.5±0.8 kg,
p<0.001). However, there were no significant inter-group differences with respect to these
three parameters (p = 0.172; p = 0.194; p = 0.135, respectively). Of note, FM decreased signifi-
cantly in the total body and main body segments in the three groups: -2.4±0.4 vs -3.0±0.4 vs
-2.1±0.4 kg in the trunk, -0.5±0.1 vs -0.6±0.1 vs -0.4±0.1 kg in the android area, -0.8±0.1 vs
-0.8±0.1 vs -0.7±0.1 kg in the gynoid area for G1, G2, G3, respectively. In contrast, FFM
Table 1. (Continued)
All groups G1: LIPOXmax G2: 60% VO2max G3: GPP at home p-value
N = 136 N = 46 n = 45 n = 45
HbA1c (%) 5.5 ± 0.3 5.5 ± 0.4 5.5 ± 0.3 5.4 ± 0.3 0.363*
Fasting plasma glucose (mmol/L) 5.0 ± 0.5 5.0 ± 0.4 4.9 ± 0.5 4.9 ± 0.5 0.535*
Insulin (m UI/L) 20.0 ± 11.3 20.8 ± 9.6 21.5 ± 13.7 17.6 ± 9.8 0.086*
HOMA-IR index 4.5 ± 2.8 4.7 ± 2.5 4.8 ± 3.5 3.9 ± 2.2 0.141*
Insulin resistant (HOMA-IR
index > 2.5)
80.0% 84.4% 80.0% 75.6% 0.574
† Data are medians and interquartile range.
‡ Data are medians and interquartile range. Otherwise, data are means ± SD or percentages. CMU: universal health coverage.
HOMA-IR index: Homeostasis Model Assessment estimated insulin resistance index. p-values refer to comparison between the three groups by one-way
ANOVA or Kruskal-Wallis non parametric tests (*) for quantitative variables, and by Chi2 test or Fisher exact tests (*) for qualitative variables.
doi:10.1371/journal.pone.0139246.t001
Table 2. Baseline exercise tests at inclusion for LIPOXmax-Réunion randomized controlled trial participants.
All groups G1: LIPOXmax G2: 60% VO2max G3: GPP at home p-value
n = 136 n = 46 n = 45 n = 45
Maximal exercise test
VO2max (L/min) 1.9 ± 0.3 1.9 ± 0.3 1.8 ± 0.2 1.9 ± 0.3 0.645
VO2max (mL/min/kg FFM) 42.5 ± 6.3 42.0 ± 6.7 43.3 ± 6.2 42.3 ± 6.1 0.632*
HRmax (bpm) 173.0 ± 11.3 170.5 ± 10.1 176.1 ± 12.0 172.5 ± 11.3 0.072*
RER 1.1 ± 0.1 1.1 ± 0.1 1.1 ± 0.1 1.1 ± 0.1 0.585*
Wmax (W) 136.0 ± 19.9 137.2 ± 21.6 132.6 ± 21.1 138.4 ± 16.2 0.429*
Metabolic exercise test
HR at LIPOXmax (bpm) 120.9 ± 13.6 118.5 ± 11.6 121.3 ± 13.7 123.0 ± 15.3 0.263*
W at LIPOXmax (W) 43.4 ± 12.1 41.9 ± 11.9 42.8 ± 12.0 45.6 ± 12.5 0.397*
W at LIPOXmax (% Wmax) 32.2 ± 8.3 30.9 ± 8.7 32.5 ± 8.4 33.1 ± 7.6 0.402*
Borg at LIPOXmax (6–20) 11.2 ± 1.1 11.0 ± 1.2 11.2 ± 1.0 11.4 ± 1.1 0.089*
VO2 at LIPOXmax (ml/min) 843.5 ± 142.3 844.2 ± 113.5 825.9 ± 154.6 860.3 ± 156.5 0.522
VO2 at LIPOXmax (% VO2max) 45.7 ± 8.3 45.2 ± 7.4 45.3 ± 9.6 46.8 ± 8.0 0.621
Maximal Lipid Oxidation
MFO (mg/min) 153.4 ± 42.9 151.6 ± 36.7 143.9 ± 38.4 164.6 ± 50.6 0.135*
MFO (mg/min/kg FFM) 3.5 ± 1.0 3.4 ± 0.9 3.4 ± 1.0 3.7 ± 1.0 0.170*
Data are means ± SD. FFM: Fat Free Mass. HR: Heart Rate. RER: Respiratory Exchange Ratio. W: Power. MFO: Maximal Fat Oxidation. p-values refer to
comparisons between the three groups by one-way ANOVA or Kruskal-Wallis non parametric tests (*).
doi:10.1371/journal.pone.0139246.t002
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evolution over time was slightly different between groups (p = 0.026) and decreased for G1 and
G2 (-0.8±0.2; -0.7±0.2 kg, respectively) while it remained stable for G3. Bonferroni correction
revealed that change in FFM only differed between G1 and G3 (p = 0.010). As shown by the
wide 95% CIs, over time the three groups exhibited a large variability in FM evolution (and on
a broader spectrum, for all body characteristics) in response to the three different
interventions.
Changes in metabolic characteristics
Out of the 109 subjects assessed at M5, the analyses of metabolic characteristics were per-
formed for the 103 subjects who had a complete longitudinal follow-up (M0, M3 and M5).
These data are summarized in Table 4. Post hoc analyses have been performed to compare
groups two by two (Tables 4 and 5).
Total cholesterol, triglycerides and FPG levels were stable over time. HDL-C/LDL-C ratio
improved in the three groups throughout the intervention with different patterns (rapid but
slight and transient response in G1, increasing response with time in G2 and G3). HbA1c
decreased over time without significant inter-group differences.
Glucose control improved throughout the intervention, the percentage of insulin-resistant
women (HOMA-IR index> 2.5) falling from 80% to 60% between M0 and M5. Insulin level
and HOMA-IR index decreased in each group (overall time-by-group interaction p = 0.014,
p = 0.011, respectively). However, the reductions in insulin and HOMA-IR index were
markedly larger for G1 when compared to G3 (G1G3 time-by-group interactions, p = 0.004
for insulin and p = 0.002, for HOMA, respectively).
In line with these results, MFO expressed in mg.min-1increased significantly over time in
each group (overall time-by-group interaction, p<0.001). As expected from the above data this
change was larger for G1 than for G3 (time-by-group interaction G1G3, p<0.001) while it
was also significant between G2 and G3 (time-by-group interaction G2G3, p = 0.004) but not
Table 3. Five-month changes in anthropometric and body composition in LIPOXmax-Réunion randomized controlled trial participants.
G1: LIPOXmax G2: 60% VO2max G3: GPP at home p-value G1 vs G2 G1 vs G3 G2 vs G3
n = 33 n = 39 n = 37
DXA characteristics
Weight (kg) -5.0 (-6.5 to -3.4) -5.4 (-6.8 to -4.0) -3.5 (-5.0 to -2.1) 0.172 - - -
BMI (kg/m²) -1.8 (-2.4 to -1.2) -2.1 (-2.7 to -1.6) -1.4 (-2.0 to -0.9) 0.194 - - -
Fat Free Mass (kg) -0.8 (-1.2 to -0.3) -0.7 (-1.1 to -0.3) 0.0 (-0.4 to 0.4) 0.026 0.820 0.010 0.032
Fat Free Mass (%) 2.2 (1.3 to 3.1) 2.7 (1.9 to 3.6) 2.6 (1.7 to 3.4) 0.703 - - -
Fat Mass (kg) -4.1 (-5.4 to -2.7) -4.7 (-5.9 to -3.5) -3.5 (-4.8 to -2.3) 0.135* - - -
Fat Mass (%) -2.3 (-3.3 to -1.4) -2.9 (-3.8 to -2.0) -2.7 (-3.6 to -1.8) 0.663 - - -
Truncal Fat Mass (kg) -2.4 (-3.3 to -1.5) -3.0 (-3.8 to -2.2) -2.1 (-2.9 to -1.3) 0.245 - - -
Android Fat Mass (kg) -0.5 (-0.6 to -0.3) -0.6 (-0.7 to -0.4) -0.4 (-0.5 to -0.2) 0.169 - - -
Gynoid Fat Mass (kg) -0.8 (-1.0 to -0.5) -0.8 (-1.1 to -0.6) -0.7 (-0.9 to -0.4) 0.441* - - -
Truncal Fat Free Mass (kg) -0.5 (-0.9 to -0.1) -0.7 (-1.1 to -0.4) -0.2 (-0.6 to 0.1) 0.148 - - -
Android Fat Free Mass (g) -95.1 (-158.3 to -31.8) -112.1 (-171.0 to -53.2) -11.9 (-71.6 to 47.9) 0.046 0.702 0.059 0.020
Gynoid Fat Free Mass (g) -139.5 (-268.2 to -10.8) -157.3 (-277.2 to -37.3) 39.7 (-81.8 to 161.3) 0.100* - - -
Data are changes from M0 to M5 (M5 minus M0): mean (95% conﬁdence interval). M5: ﬁfth month of intervention. p values refers to comparison between
the three groups by one-way ANOVA model or Kruskal-Wallis non parametric test (*). If p<0.05, post-hoc analysis was performed with Student’s test to
compare groups two-by-two at p = 0.0167 signiﬁcance level according to Bonferroni’s method.
doi:10.1371/journal.pone.0139246.t003
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between G1 and G2. Alternatively, MFO expressed in mg.min.kg FFM-1 increased significantly
in each group (time-by-group interaction, p<0.001), and so defined, this change was larger for
G1 than for G2 or G3. Additionally, G1G2 and G1G3 time-by-group interactions were both
significant (p = 0.016 and p<0.001, respectively) while it was not significant between G2 and
G3.
Importantly, we found no correlation between the indicators of insulin resistance and those
of MFO.
Discussion
To the best of our knowledge, in the context of combined lifestyle interventions used for pre-
venting T2DM, the LIPOXmax-Réunion program is the first RCT that aimed at body weight
reduction by targeting fat oxidation as the principal fuel of energetic expenditure in a popula-
tion of young overweight or obese women. All other things being equal (i.e., baseline inclusion
characteristics, baseline exercise data, fruits and vegetables diet), the findings reveal a very sig-
nificant FM reduction over time with the three training programs, but an absence of superiority
of the LIPOXmax intervention to decrease FM despite a better glucose control as indicated by
larger decreases of insulin level and HOMA-IR index in this group, as compared with "60%
VO2max" and "GPP at-home", the two other competitive programs tested in our trial. It is
noteworthy that a five-month exercise regimen guided by the LIPOXmax did not result in
superiority despite higher MFO values in the LIPOXmax group.
These outcomes are consistent with the current literature in the field, whose analyses sug-
gest an inconstant benefit of LIPOXmax training. Thus, a recent meta-analysis of 15 studies
exploring body composition changes after LIPOXmax training provides evidence that the
range of FM reduction varied between 0 and -12.1 kg and that its pooled effect estimate was of
−4.1 kg (95% CI: −5.8 to −2.3 kg; p<0.001) [26]. Such heterogeneity in efficacy was first attrib-
uted to the various origins of the populations targeted by LIPOXmax RCTs pooled in the
meta-analysis. These included people as diverse as T2DM or MS subjects, obese teenagers, or
subjects suffering a human immunodeficiency virus infection. Second, in the different RCTs,
the implementation of the LIPOXmax program was recognized to vary due to the different
durations of intervention, different amounts of weekly sessions, or training combined with diet
or not. Thus, beyond theoretical promise, these data still make difficult the interpretation of
LIPOXmax RCTs.
Table 5. Post-hoc analysis (Repeated–measures ANOVA P values) for longitudinal evolution of metabolic characteristics (month-0, month-3 and
month-5).
All groups G1 vs G2 G1 vs G3 G2 vs G3
t g t x g t g t x g t g t x g t g t x g
Glucose proﬁle
Insulin (m UI/L) < 0.001 0.186 0.015 < 0.001 0.407 0.756 < 0.001 0.089 0.004 < 0.001 0.250 0.025
HOMA-IR index < 0.001 0.164 0.011 < 0.001 0.405 0.563 < 0.001 0.084 0.002 < 0.001 0.199 0.042
Maximal Lipid Oxidation
MFO (mg/min) < 0.001 0.262 < 0.001 < 0.001 0.110 0.021 < 0.001 0.188 < 0.001 < 0.001 0.933 0.004
MFO (mg/min/kg FFM) (n = 109) < 0.001 0.691 < 0.001 < 0.001 0.396 0.016 < 0.001 0.580 < 0.001 < 0.001 0.775 0.027
HOMA-IR index: HOmeostasis Model Assessment estimated insulin resistance index. MFO: Maximal Fat Oxidation. FFM: Fat Free Mass. Repeated-
measures ANOVA P values represent the main effects of time (t), g (group) and the interaction effect (time *group). Post-hoc analysis (G1 vs G2, G1 vs
G3, G2 vs G3) was performed to compare groups two-by-two at p = 0.0167 signiﬁcance level according to Bonferroni’s method.
doi:10.1371/journal.pone.0139246.t005
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In our RCT, the fact of equalizing the endurance intensity in the LIPOXmax and VO2max
groups with similar energy expenditures may have contributed to the same magnitude of FM
reduction in both groups. Indeed, several trials have shown that isocaloric training groups with
different intensities reported similar effects [36–39]. This has led some contributors to con-
clude that, when matched for energy cost, low- and high-intensity exercises are equally effective
in reducing visceral FM. In contrast, low-intensity challenges proved more effective in using
lipids and decreasing FM than high-intensity ones [40–42] Thus, the search for a balance
between an acceptable energetic cost and the potential for long-term benefits of low-intensity
programs, with the aim of targeting more specifically the "substrate of interest", has led experts
to explore the concept of "steady state" exercises, which should theoretically allow both similar
energy expenditure but higher lipid utilization under various intensities. In this emerging
framework, high-intensity steady state (HISS) and also high-intensity intermittent exercises
(HIIE) were shown to be more effective than traditional low to moderate steady state exercises
(SSE) [43–46]. Interestingly, a recent review suggests that HIIE may have a greater impact on
body composition compared with SSE [47]. Hence, one RCT has sought to compare the effects
of HIIE and LIPOXmax training programs in T2DM obese patients matched on age, BMI and
HbA1c [48]. Its results show evidence that HIIE and LIPOXmax exhibit distinct interesting
patterns for DT2 and CVD prevention. On one hand, HIEE improved VO2 peak, reduced sys-
tolic blood pressure at rest and total cholesterol. On the other hand, LIPOXmax improved lipid
oxidation, decreased FM and HbA1c. Thus the benefits of the two strategies could be synergis-
tic and combined in the management of obese and diabetic subjects. This being said, the opti-
mal intensity of PA should be guided by the parameters we wish to improve (FM loss, FFM
increase, glucose control, VO2-peak improvement, control of CVD risk factors).
In our RCT, we observed that FFM decreased in both the LIPOXmax and VO2max groups
while it remained stable in the "GPP at-home" control group. We hypothesize that the partici-
pants enrolled in the control group may have varied their daily PA practice at points to mobi-
lize other muscle groups to maintain their lean body mass. This was confirmed by the study of
PA booklets in the "GPP at-home group" which revealed a good observance of a moderate-
intensity and varied PA (i.e., on average more than two types of PA per woman). We believe
that this broad diversity of PA may have partially explained the conservation of FFM.
It is also important to emphasise that among the 80% of insulin-resistant (HOMA-IR
index> 2.5) obese women at inclusion enrolled in our RCT, a quarter were no longer insulin
resistant at the end of the intervention regardless of training program. This finding may be
attributed to the benefit of a combined lifestyle intervention whatever the nature of the PA
practised, as suggested by the absence of correlation between the level of insulin resistance and
values of MFO indicators. However, the improvement in glucose control (measured both on
insulin level and HOMA-IR index) and the increase in MFO indicators were much more pro-
nounced in the LIPOXmax group than in the "GPP at-home" group (-6.7 vs -1.6 mUI/L; -1.6 vs
-0.3; +72.0 vs +18.6 mg.min-1 or +1.7 vs +0.5 mg.min.kg FFM-1 respectively for insulin,
HOMA-IR index and MFO). Moreover, MFO values expressed in mg.min.kg FFM-1 increased
more in the LIPOXmax group than in the VO2max group, confirming the expected effect of
our targeted intervention on lipid metabolism. Such an improvement in glucose control under
the LIPOXmax challenge is in line with previous findings after endurance training in obese or
MS subjects [18,22], which is explained by increased lipid oxidation in the muscles of obese
subjects during exercise [49]. Subsequently, regular and moderate PA is usually prescribed in
obese subjects at-risk of T2DM based on the assumption that lipid oxidation could have a cen-
tral role in glycemic levels [50].
According to our results, the kinetics is not linear and most of the benefits are obtained
within 3 months. In fact, it is not surprising: first, the two periods are not equal, the first one
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(M0 to M3) being longer than the second one. Then, after initial weight loss, increasing volume
of physical activity appears to be important to prevent weight regain [9]. To increase FM loss
between M3-M5 it would have been better to adjust PA program in each group (duration and
re-evaluation of the adapted intensity).
Finally, based on the lesson issued from the “GPP at-home group”, our findings should
encourage the health professionals to continue to prescribe some PA for muscular strengthen-
ing purpose, while in turn, the lesson issued from the LIPOXmax group could give an impetus
to target a better glucose control through low-intensity exercises in the future studies.
However, in light of new evidence linking the intensity of lipid oxidation to FM loss [51–
53], our inconclusive RCT may have some limitations. First, we may have slightly overesti-
mated the precision required in sample size calculation (±2.0 SD) given that we observed dis-
persion in FM reduction estimates (95% CI, -2.7 to +5.4 kg) between the LIPOXmax and
VO2max groups. This has led to a dramatic fall of statistical power from 80% to 33%. This
approximation in SD estimation was due to the lack of previously published work evaluating
the LIPOXmax program in young, overweight or obese women. Second, the beneficial effect
appears to level off at 5 months and most of the gain of LIPOXmax intervention was obtained
within 3 months, so that we may think that the duration of the intervention (five months) may
have been too short to demonstrate any benefit on FM and a fortiori on fasting glucose profile.
Third, five of the women in the VO2max group may indeed have worked in the LIPOXmax
zone out of a range of intensities that elicit a minimum of 90% of MFO. These women exhib-
ited a -4.4 kg (±1.4 SD) FM reduction at M5. This observation may have flattened the contrast
between LIPOXmax and VO2max groups in FM reduction. A sensitivity analysis excluding
these women did not change the overall meaning of our results.
In conclusion, our RCT does not support the superiority of the LIPOXmax training on 60%
VO2max or GPP-at-home for FM reduction in young overweight or obese women. Neverthe-
less, our findings suggest a potential benefit of a combined lifestyle intervention based on
LIPOXmax to improve glucose and lipid metabolism. More than ever, deciphering the mecha-
nisms and long-term outcomes of MFO exercises is required before promoting the usefulness
of such a strategy in helping to prevent T2DM.
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